References
1. Zhu N, Zhang D, Wang W, Li X, Yang
B, Song J, et al. A novel coronavirus from patients with pneumonia in
China, 2019. New England journal of medicine. 2020.
2. Liu Y, Lee JM, Lee C. The
challenges and opportunities of a global health crisis: the management
and business implications of COVID-19 from an Asian perspective. Asian
Business & Management. 2020;19:277-97.
3. Huang AT, Garcia-Carreras B,
Hitchings MD, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic
review of antibody mediated immunity to coronaviruses: antibody
kinetics, correlates of protection, and association of antibody
responses with severity of disease. MedRxiv. 2020.
4. Iacobellis G. COVID-19 and
diabetes: Can DPP4 inhibition play a role? Diabetes research and
clinical practice. 2020;162.
5. Roncon L, Zuin M, Rigatelli G,
Zuliani G. Diabetic patients with COVID-19 infection are at higher risk
of ICU admission and poor short-term outcome. Journal of Clinical
Virology. 2020;127:104354.
6. Malavazos AE, Corsi Romanelli MM,
Bandera F, Iacobellis G. Targeting the adipose tissue in COVID‐19.
Obesity. 2020;28(7):1178-9.
7. Wang F, Qu M, Zhou X, Zhao K, Lai
C, Tang Q, et al. The timeline and risk factors of clinical progression
of COVID-19 in Shenzhen, China. Journal of Translational Medicine.
2020;18(1):1-11.
8. Halvatsiotis P, Kotanidou A,
Tzannis K, Jahaj E, Magira E, Theodorakopoulou M, et al. Demographic and
clinical features of critically ill patients with COVID-19 in Greece:
The burden of diabetes and obesity. Diabetes research and clinical
practice. 2020;166:108331.
9. Alkundi A, Mahmoud I, Musa A,
Naveed S, Alshawaf M. Clinical characteristics and outcomes of COVID-19
hospitalized patients with diabetes in UK: A retrospective single centre
study. Diabetes Research and Clinical Practice. 2020.
10. Zhang J, Kong W, Xia P, Xu Y, Li
L, Li Q, et al. Impaired fasting glucose and diabetes are related to
higher risks of complications and mortality among patients with
coronavirus disease 2019. Frontiers in endocrinology. 2020;11:525.
11. Moher D, Liberati A, Tetzlaff J,
Altman DG, Group P. Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement. PLoS medicine. 2009;6(7):e1000097.
12. de Almeida-Pititto B, Dualib PM,
Zajdenverg L, Dantas JR, De Souza FD, Rodacki M, et al. Severity and
mortality of COVID 19 in patients with diabetes, hypertension and
cardiovascular disease: a meta-analysis. Diabetology & metabolic
syndrome. 2020;12(1):1-12.
13. Wells GA, Shea B, O’Connell Da,
Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in meta-analyses.
Oxford; 2000.
14. Azharuddin M, Adil M, Sharma M,
Gyawali B. A systematic review and meta-analysis of non-adherence to
anti-diabetic medication: Evidence from low‐and middle‐income countries.
Authorea Preprints. 2021.
15. Lim S, Bae JH, Kwon H-S, Nauck
MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical
management. Nature Reviews Endocrinology. 2020:1-20.
16. Holman N, Knighton P, Kar P,
O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related
mortality in people with type 1 and type 2 diabetes in England: a
population-based cohort study. The lancet Diabetes & endocrinology.
2020;8(10):823-33.
17. Huang I, Lim MA, Pranata R.
Diabetes mellitus is associated with increased mortality and severity of
disease in COVID-19 pneumonia–a systematic review, meta-analysis, and
meta-regression. Diabetes & Metabolic Syndrome: Clinical Research &
Reviews. 2020;14(4):395-403.
18. Chen T, Wu D, Chen H, Yan W, Yang
D, Chen G, et al. Clinical characteristics of 113 deceased patients with
coronavirus disease 2019: retrospective study. bmj. 2020;368.
19. Apicella M, Campopiano MC,
Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with
diabetes: understanding the reasons for worse outcomes. The lancet
Diabetes & endocrinology. 2020.
20. Sanyaolu A, Okorie C, Marinkovic
A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on
Patients with COVID-19. SN comprehensive clinical medicine. 2020:1-8.
21. Lei M, Lin K, Pi Y, Huang X, Fan
L, Huang J, et al. Clinical Features and Risk Factors of ICU Admission
for COVID-19 Patients with Diabetes. Journal of diabetes research.
2020;2020.
22. Wu C, Chen X, Cai Y, Zhou X, Xu
S, Huang H, et al. Risk factors associated with acute respiratory
distress syndrome and death in patients with coronavirus disease 2019
pneumonia in Wuhan, China. JAMA internal medicine. 2020;180(7):934-43.
23. Ata F, Almasri H, Sajid J, Yousaf
Z. COVID-19 presenting with diarrhoea and hyponatraemia. BMJ Case
Reports CP. 2020;13(6):e235456.
24. Qiu H, Wu J, Hong L, Luo Y, Song
Q, Chen D. Clinical and epidemiological features of 36 children with
coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational
cohort study. The Lancet Infectious Diseases. 2020;20(6):689-96.
25. Belkhadir J. COVID-19 and
diabetes from IDF MENA region. diabetes research and clinical practice.
2020;166:108277.
26. Li G, Deng Q, Feng J, Li F, Xiong
N, He Q. Clinical characteristics of diabetic patients with COVID-19.
Journal of diabetes research. 2020;2020.
27. Abdi A, Jalilian M, Sarbarzeh PA,
Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the
current evidences. Diabetes research and clinical practice.
2020;166:108347.
28. Wang Z, Du Z, Zhu F. Glycosylated
hemoglobin is associated with systemic inflammation, hypercoagulability,
and prognosis of COVID-19 patients. Diabetes research and clinical
practice. 2020;164:108214.
29. Yang X, Yu Y, Xu J, Shu H, Liu H,
Wu Y, et al. Clinical course and outcomes of critically ill patients
with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
retrospective, observational study. The Lancet Respiratory Medicine.
2020;8(5):475-81.